Drug Trial Radar · NCT07029828
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Sep 10, 2025
Primary completion
Jun 26, 2030
Study completion Jun 26, 2030
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss. This study is seeking participants who have: * previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031). * at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031). * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports. All participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial. Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial. The study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home. The study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.
Conditions
- Severe Alopecia Areata
Interventions
Ritlecitinib higher doseDrug
Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
Ritlecitinib lower doseDrug
Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (AEs).Time frame: From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).
- Incidence of Serious Adverse Events (SAEs) and AEs leading to permanent discontinuation from the study.Time frame: From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).
Locations
69 sites in 9 countries. Site status is shown where the registry gives one.
University of California~ Irvine
Irvine, California · Recruiting
Southern California Clinical Research
Santa Ana, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Children's National Hospital
Washington D.C., District of Columbia · Recruiting
Pediatric Skin Research
Miami, Florida · Recruiting
Endeavor Health Clinical Operations
Skokie, Illinois · Recruiting
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana · Recruiting
Kindred Hair and Skin Center
Marriottsville, Maryland · Recruiting
Michigan Dermatology Institute
Waterford, Michigan · Recruiting
Skin Specialists, PC dba Schlessinger MD
Omaha, Nebraska · Recruiting
University of New Mexico Health Sciences Center
Albuquerque, New Mexico · Recruiting
University of New Mexico-IDS Pharmacy
Albuquerque, New Mexico · Recruiting
Northwest Dermatology Institute
Portland, Oregon · Recruiting
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania · Recruiting
Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
Charleston, South Carolina · Recruiting
Dell Children's Medical Center
Austin, Texas · Recruiting
Driscoll Children's Hospital
Corpus Christi, Texas · Recruiting
3A Research
El Paso, Texas · Recruiting
Austin Institute for Clinical Research
Pflugerville, Texas · Recruiting
Texas Dermatology and Laser Specialists
San Antonio, Texas · Recruiting
Children's Wisconsin
Milwaukee, Wisconsin · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Children's hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Beijing Tongren Hospital affiliated to Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Beijing Tongren Hospital affiliated to Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Hunan Children's Hospital
Changsha, Hunan, China · Recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Recruiting
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Chengdu Women and Children Center Hospital
Chengdu, Sichuan, China · Recruiting
The First People's Hospital of Hangzhou
Hangzhou, Zhejiang, China · Recruiting
Hangzhou Third Hospital
Hangzhou, Zhejiang, China · Recruiting
Fakultní Nemocnice Brno
Brno, Czechia · Recruiting
Fakultni Nemocnice Plzen
Pilsen, Czechia · Recruiting
Prof. MUDr. Petr Arenberger, DrSc., MBA
Prague, Czechia · Recruiting
Fakultni nemocnice Bulovka
Praha 8 - Libeň, Czechia · Recruiting
Hospices Civils de Lyon - CIC - Hopital Louis Pradel
Bron, France · Recruiting
Hospices Civils de Lyon - Hopital Femme Mere Enfant
Bron, France · Recruiting
CHU de Dijon Bourgogne
Dijon, France · Recruiting
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.